Haya Therapeutics has secured $65m in Series A funding to expedite the clinical development of HTX-001 for treating heart ...

Bavarian Nordic is successfully navigating a sentiment-changing vaccine landscape, posting Q1 revenues significantly up from ...

Globaldata's analysis focuses on three key indicators, which include HTA outcomes in the 5EU and the entry of newly priced ...

HLS Therapeutics has signed an agreement with Esperion Therapeutics for commercialising Nexletol and Nexlizet in Canada.

Novo Nordisk has cut its sales and profits forecasts for 2025 due to lower demand in the US for blockbuster weight loss and ...

Developing orphan drugs involves navigating intricate regulatory landscapes, financial risks, and limited clinical data. To ...

BioVaxys Technology and Sona Nanotech have signed an agreement to develop cancer therapeutics, utilising the DPX platform ...

As scientists explore treating genetic disorders before birth, the promise of foetal gene therapy is growing—but there are ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

Viralgen has partnered biotech company Trogenix, aiming to accelerate the development of gene therapy for glioblastoma.